Oncologix Tech, Inc.

As of May 31, 2015, Oncologix Tech, Inc. carries a market capitalization of 913,262.23, placing it among publicly traded companies globally. Its enterprise value stands at 4.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2015, Oncologix Tech, Inc. has 276.75M shares outstanding.

These figures are as of May 31, 2015. The price-to-sales ratio is 0.12, and the price-to-book ratio stands at -0.77.

These figures are as of May 31, 2015. The EV/Sales ratio of 0.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.02M versus a market cap of 913,262.23, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2015, Oncologix Tech, Inc. maintains a current ratio of 0.28, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -271.49, indicating conservative leverage, while an interest coverage ratio of -0.50 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended May 31, 2015. Return on assets (ROA) is negative at -55.92, reflecting losses generated across the asset base. The company generates approximately 575,763.25 in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 43.24 indicates how many times Oncologix Tech, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 16, 2026, Oncologix Tech, Inc.'s stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended May 31, 2015, Oncologix Tech, Inc. generated 4.61M in revenue and converted that into -1.75M in net income, yielding earnings per share of -0.01. EBITDA reached -572,640.00, while operating income came in at -592,659.00.

As of May 31, 2015, Oncologix Tech, Inc. holds 120,485.00 in cash and equivalents against 3.23M in total debt, resulting in a net debt position of 3.11M. Total book value stands at -1.19M, with working capital of -3.35M providing operational flexibility.

Oncologix Tech, Inc. produced -570,250.00 in operating cash flow over the twelve months ended May 31, 2015. After subtracting -2,033.00 in capital expenditures, free cash flow totaled -572,283.00 - equivalent to 0.00 per share.

Over the twelve months ended May 31, 2015, Oncologix Tech, Inc. posted a gross margin of 20.82, reflecting its pricing power and cost economics. The operating margin of -12.87 and net profit margin of -37.98 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2015. Free cash flow yield is negative at -100.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -116.87, meaning Oncologix Tech, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Oncologix Tech, Inc.'s most recent stock split took place on May 19, 2011 with a 4:1 split ratio.

As of May 31, 2015, Oncologix Tech, Inc. has an Altman Z-Score of -49.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.